mRNA and beyond: Opportunities for US biologics
The success of mRNA vaccine technology could be one of the new opportunities for US pharmaceutical manufacturing looking forward, with pandemic investments helping turbocharge the sector.
The success of mRNA vaccine technology could be one of the new opportunities for US pharmaceutical manufacturing looking forward, with pandemic investments helping turbocharge the sector.
Adoption of single-use technologies has grown exponentially over the last decade: but what will drive the tech forward in the coming years?
There is “some way to go” before UnitedHealth Group has the clarity to make a coverage decision on Biogen’s Alzheimer’s disease drug Aduhelm, according to the CEO of the healthcare company.
Sanofi will acquire clinical-stage mRNA therapeutics company Translate Bio for $3.2bn.